UCB’s Shift Toward Smarter Oversight: From Fully Outsourced to CRO Agnostic
“Oversight is sometimes seen as a negative thing or a challenge, but with the new regulation you could almost see it as an opportunity to build on what you have, optimize, all for the betterment of patients.”
At the Clinical Oversight Forum in Copenhagen, leaders from UCB and Veeva shared real-world lessons from UCB’s iHome journey, and why a hybrid, CRO-agnostic approach can deliver greater flexibility, transparency, and value for patients—especially in rare disease trials.
Discover:
- The limitations of fully outsourced studies that pushed UCB to rethink oversight and operating models (00:27)
- How becoming CRO-agnostic created flexibility across processes, people, and platforms (01:54)
- Why rare disease trials accelerated the move toward in-house study management and deeper site engagement (02:08)
- The biggest challenges in transitioning from hybrid models to a fully internalized operating model—and how UCB navigated them (04:08)
- Why R3 oversight isn’t “plug and play,” and how sponsors can turn regulation into an opportunity for smarter outsourcing (09:30)
- Practical change-management insights for sponsors considering new oversight models (11:46)
